Johnson & Johnson CEO Bill Weldon’s painful year
What started last year as a series of small drug recalls at Johnson & Johnson exploded this summer into a full-blown crisis in quality control. But for months there was nary a peep from CEO Bill Weldon.
It wasn't until late August, after McNeil Consumer Healthcare, the division of J&J (JNJ, Fortune 500) that makes over-the-counter drugs, had instituted eight recalls, that Weldon emerged, granting multiple interviews in which he promised to rectify McNeil's quality problems. He told Fortune that he had created a new position: an operations chief who will oversee quality across J&J and report directly to him. Weldon also said the company had been busy inspecting facilities at all of its 250 operating companies, adding, "This is not a systemic problem at J&J." [For a diagnosis of what went wrong, read "Why J&J's headache won't go away."]
That assertion was quickly undercut. About a week after Weldon proclaimed McNeil an anomaly, the company issued two more recalls -- both in divisions completely separate from McNeil. One was for contact lenses made by Vision Care, and the other involved hip implants made by DePuy.
- CVS Ramps Up Retail Clinics with Provider Affiliations
- 4 Tectonic Shifts Shaking Up Healthcare
- Medical Errors Third Leading Cause of Death, Senators Told
- As States Regulate Provider Competition, Common Threads Emerge
- Contradictory Obamacare Rulings Issued by Appellate Courts
- Chronic Disease Care Costs Get Bipartisan Attention
- As HIPAA Breaches Accelerate, Tools Lag
- Roundtable: Life After a Healthcare Organization Acquisition
- Recruiting Retired Clinicians
- Mayo Tops U.S. News Best Hospitals Rankings